Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
741-760 of 1,694 trials

Advanced Sarcomas: Pembrolizumab and Cabozantinib Study

We are investigating the effects of a combination of pembrolizumab and cabozantinib in patients with advanced sarcomas. The goal is to see if this treatment can help prevent disease progression and improve overall outcomes.

Advanced Metastatic Sarcomas>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Tardive Dyskinesia: Safety Study of ADE513

We are testing a new medication for people with moderate to severe tardive dyskinesia to see how safe it is for long-term use. The study will also look at its long-term effects on managing symptoms.

Tardive Dyskinesia1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyPsychiatry

Autoimmune Diseases: Ublituximab Administration Study

We are evaluating how well ublituximab works when given through an IV or as a subcutaneous injection in patients with autoimmune diseases. This study aims to understand the drug's effects and how it moves through the body.

Relapsing Multiple SclerosisMyasthenia Gravis1-2 yearsSafety phase (I)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineNeurology

HER2+ Cancer Treatment: Zongertinib Study

We are exploring the safety and effectiveness of zongertinib, alone and with other treatments, for patients with advanced HER2+ metastatic breast and gastric cancers. This study aims to find the best dose and understand how it may help manage these cancers.

Gastroesophageal Junction AdenocarcinomaEsophageal AdenocarcinomaMetastatic Breast CancerSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyOncology

RAS G12C-Mutated Non-Small Cell Lung Cancer: RMC-6291 Study

We are studying a new treatment combining RMC-6291 with pembrolizumab and other therapies for patients with RAS G12C-mutated lung cancer. The goal is to evaluate safety and early signs of effectiveness.

Non-small Cell Lung CancerSafety phase (I)No PlaceboInvestigational MedicinesOncologyPulmonology

Non-Small Cell Lung Cancer: RMC-6236 with Pembrolizumab

We are studying a new treatment combining RMC-6236 and pembrolizumab for patients with advanced RAS-mutated non-small cell lung cancer. The goal is to evaluate its safety and potential effectiveness, with or without chemotherapy.

Non-small Cell Lung CancerSafety phase (I)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

MEPENDAX: Axitinib and Etoposide for Pediatric Brain Tumors

We are studying a new treatment combining axitinib and oral etoposide for children and young adults with relapsing medulloblastoma or ependymoma. The goal is to find the safest dose and see if it helps improve survival.

MedulloblastomaEpendymoma>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesNeurologyOncologyPediatrics

Ovarian and Breast Cancer: zAvatar Test Study

We are exploring whether the zAvatar test can help guide treatment decisions for patients with relapsed ovarian cancer and metastatic breast cancer. This study compares outcomes from the zAvatar test approach to standard care.

Breast CancerOvarian CancerMonitoring phase (IV)No PlaceboStandard MedicinesOncology

Ulcerative Colitis: Oral Mesalazine Treatment

We are studying an oral medication for people with mild to moderate ulcerative colitis to see if it helps induce remission of symptoms. The trial will assess various measures of improvement after treatment.

Ulcerative Colitis3-6 monthsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Bipolar Disorder Type II: Lithium vs. Lamotrigine Study

We are comparing the effects of lithium and lamotrigine on mood stabilization in people with bipolar disorder type II. The goal is to see which treatment may better reduce symptoms and improve daily functioning.

Bipolar Disorder, Type II1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemotePsychiatry

Alzheimer's Disease: Efavirenz Study

We are investigating whether Efavirenz can affect certain biomarkers in people with early Alzheimer's Disease. This study aims to understand its safety and how it works in the body.

Alzheimer's Disease3-6 monthsSafety phase (I)Efficacy phase (II)Standard MedicinesNeurology

Crohn's Disease: Upadacitinib for Children

We are studying the effects of Upadacitinib in children with active Crohn's disease who haven't had success with other treatments. The goal is to see if it helps them achieve better health outcomes.

Crohn's Disease>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Radiprodil for Children with GRIN-related Disorder

We are studying a new medication to see if it is safe and helps reduce seizures and improve behavior in children with GRIN-related disorder. This trial aims to find the right dose and understand its effects over time.

GRIN-related Disorder>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesNeurologyPediatrics

Ulcerative Colitis: Tofacitinib for Children

We are studying whether the oral medication tofacitinib can help children with moderately to severely active ulcerative colitis achieve remission. The trial will also look at how well the medication works and how it is accepted by young patients.

Ulcerative Colitis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Ponatinib for Pediatric Leukemias and Solid Tumors

We are studying the safety and effectiveness of ponatinib in children with recurrent or hard-to-treat leukemias and solid tumors. This trial aims to help those who have not responded to other therapies.

Acute Myeloid LeukaemiaChronic Myeloid Leukaemia1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Heart Failure: Vicadrostat and Empagliflozin Study

We are testing if the combination of vicadrostat and empagliflozin helps people with heart failure feel better and reduces serious heart-related events. This study is for individuals with specific heart failure symptoms and heart function.

Heart FailureConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Fabry Disease: Venglustat Tablets

We are studying whether venglustat can improve heart health in adults with Fabry disease compared to standard treatments. The trial also looks at its effects on kidney function and overall well-being.

Fabry's Disease1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCardiologyHematologyInternal Medicine

Atrial Fibrillation: New Drug Treatment After Stent Surgery

We are studying whether a simpler medication regimen can safely prevent blood clots and serious heart issues in patients with irregular heartbeat after coronary stent implantation. This trial compares it to the current standard treatment involving multiple medications.

Acute Coronary SyndromeAtrial FibrillationAtrial Flutter>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Constipation Prevention in Critically Ill Children: PEG3350+E Treatment

We are studying whether a special solution can help prevent constipation in critically ill children. The trial also looks at the safety of this treatment and compares stool consistency in different patient groups.

Constipation≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyPediatrics

Metastatic Colorectal Cancer: Regorafenib with Chemotherapy

We are studying whether combining Regorafenib with metronomic chemotherapy and low-dose aspirin helps patients with chemo-resistant metastatic colorectal cancer live longer without disease progression. We will also look at quality of life and treatment side effects.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology